Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...
Pharm Exec1d
Novartis Commits $75 Million to ZERO Prostate Cancer Initiative
According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.
FiercePharma3d
Novartis pumps $7.5M into push to save 100,000 lives from prostate cancer by 2035
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
ZERO Prostate Cancer Launches Bold $20 Million 'Blitz The Barriers' Initiative to Close Gaps in Prostate Cancer Survival in Highest-Risk Communities
ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...
pharmaphorum29d
ASCO21: Novartis' prostate cancer radiotherapy extends survival
Novartis' big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options live ...
precisionmedicineonline1d
Real-World Studies Aim to Optimize Treatment Sequence for Novarits' Pluvicto in Prostate Cancer
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
Combining protein therapy and focused ultrasound therapy can improve cancer treatment
Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...